Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(22):1682-1683; doi:10.1093/jnci/93.22.1682
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Illman, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Illman, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 22, 1682-1683, November 21, 2001
© 2001 Oxford University Press

NEWS

Proposals to Speed Up European Drug Approval Process Questioned

John Illman

A recent study suggested that the European drug approval system takes twice as long to approve cancer drugs than does the U.S. Food and Drug Administration, adding fuel to recent criticism of the European drug approval process.

The European Commission has unveiled plans to speed up the approval process, but these are not expected to take effect until 2003—8 years after the formation of the European Medicines Evaluation Agency. The EMEA, which functions as the European counterpart to the U.S. . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?